The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States
Abstract
Congenital toxoplasmosis (CT) is a parasitic disease that can cause significant fetal and neonatal harm. Coordinated efforts by pregnant women, researchers, physicians, and health policy makers regarding potential primary and secondary preventive measures for CT and their implementation may lead to a lower incidence of CT as well as lower morbidity and mortality rates associated with CT. In the United States, the age-adjusted seroprevalence of Toxoplasma gondii among women of childbearing age (15–44 years) has declined over time (15%, 11%, and 9% in 1988–1994, 1999–2004, and 2009–2010, respectively; among US-born women only, the seroprevalence rates during these time periods were 13%, 8%, and 6%, respectively). Thus, approximately 91% of women of childbearing age in the United States are susceptible to Toxoplasma infection. Should these women become infected during pregnancy and remain undiagnosed and untreated, they could deliver an infant with CT. However, the incidence of acute primary infection is likely very low in the current era and is probably much lower than the 1.1 in 1000 pregnant women originally reported in 1960s.There are 3 ways CT can occur. First, CT can develop through transmission of T gondii to the fetus from a previously seronegative, immunocompetent mother who acquired acute primary infection during pregnancy or within 3 months before conception. Second, CT can occur through reactivation of toxoplasmosis in a previously T gondii–immune pregnant woman who was severely immunocompromised during pregnancy. Third, CT can result after reinfection of a previously immune pregnant mother with a new, more virulent strain (eg, after international travel or after eating undercooked meat from areas where more virulent atypical strains predominate).In cohorts of women who have been screened routinely during pregnancy and treated accordingly once primary infection was diagnosed, the mother-to-child transmission (MTCT) rate was <5% after an acute primary maternal infection very early in pregnancy, but MTCT rates were much higher with acute maternal infections acquired later in pregnancy (15%, 44%, and 71% after maternal seroconversions [acute primary infections] at 13, 26, and 37 weeks of gestation, respectively).1 The risk of MTCT in untreated women may be higher. Factors (any or a combination) associated with an increased risk of MTCT are as follows: (1) acute T gondii infection during pregnancy, (2) immunocompromising conditions, (3) lack of antepartum treatment, (4) high T gondii strain virulence, and (5) high parasite load.The incidence of CT, according to early cumulative published data from the New England Newborn Screening Program over a 12-year period (1988–1999), was 0.91 cases per 10 000 live births, which would have translated to the birth of approximately 365 infants with CT in the United States each year. The incidence of CT decreased after 1999 and, over the past 9 years (2006–2014), was approximately 0.23 cases per 10 000 live births. The true incidence of CT in the United States might be higher, because the sensitivity of the newborn screening test (blot-spot immunoglobulin [Ig] M test) is approximately 50% to 75%, and fetal losses attributable to severe CT were not counted.Recent data from the National Reference Laboratory for Toxoplasmosis in the United States showed that 85% of 164 infants with CT identified over a period of 15 years were severely affected: 92% had chorioretinitis, 80% had intracranial calcifications, 68% had hydrocephalus, and 62% had all of these manifestations. These data were based on cases referred to reference toxoplasmosis centers in the United States, and they were not population based. The generalizability of these findings at a population level may be limited. The rate of symptomatic CT among infants diagnosed via the New England Newborn Screening program (1986–1992) was 40% (25% with eye disease at birth or follow-up and 29% with central nervous system [CNS] disease). However, in neonatal screening programs, spontaneous abortion, fetal demise, and pregnancy terminations attributable to severe CT are not captured. The rates of symptomatic CT in European cohorts are much lower than in the United States. Possible reasons for those disparities include differences in T gondii strains and the absence of antepartum screening and treatment of CT in the United States. In addition, differences between population-based, prospectively identified CT cases versus more selected cases referred to reference centers may bias reporting estimates.Evidence in favor of antepartum treatment benefits to decrease the risk of MTCT of CT is variable and accumulated from several observational studies. One randomized therapeutic trial has been conducted in pregnancy.2 European data from the Systematic Review on Congenital Toxoplasmosis (SYROCOT) international consortium, which performed a meta-analysis of individual patient data published in 2007,1 suggested that the odds of MTCT wer
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Foodborne illness acquired in the United States—Major pathogens
Scallan, E., Hoekstra, R. M., Angulo, F. J., Tauxe, R. V., Widdowson, M.-A., Roy, S. L., Jones, J. L., & Griffin, P. M. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1701.p11101 · Cited by 7,657
Montoya, J., & Liesenfeld, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16412-x · Cited by 3,232
Howe, D. K., & Sibley, L. D. (1995) · Journal of Infectious Diseases · doi:10.1093/infdis/172.6.1561 · Cited by 1,445
Toxoplasma gondii infection in humans and animals in the United States
DUBEY, J., & JONES, J. (2008) · International Journal for Parasitology · doi:10.1016/j.ijpara.2008.03.007 · Cited by 1,091
Cook, A. J. C. (2000) · BMJ · doi:10.1136/bmj.321.7254.142 · Cited by 1,016
Virulent strains of Toxoplasma gondii comprise a single clonal lineage
Sibley, L. D., & Boothroyd, J. C. (1992) · Nature · doi:10.1038/359082a0 · Cited by 831
The global burden of congenital toxoplasmosis: a systematic review
Torgerson, P. R., & Mastroiacovo, P. (2013) · Bulletin of the World Health Organization · doi:10.2471/blt.12.111732 · Cited by 748
Toxoplasma gondii Infection in the United States: Seroprevalence and Risk Factors
Jones, J. L. (2001) · American Journal of Epidemiology · doi:10.1093/aje/154.4.357 · Cited by 742
Outbreak of toxoplasmosis associated with municipal drinking water
Bowie, W. R., King, A. S., Werker, D. H., Isaac-Renton, J. L., Bell, A., Eng, S. B., & Marion, S. A. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11105-3 · Cited by 704
Cited by
Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice
Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O., & Montoya, J. G. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00057-17 · Cited by 553
Epidemiology, Pathophysiology, Diagnosis, and Management of Cerebral Toxoplasmosis
Elsheikha, H. M., Marra, C. M., & Zhu, X.-Q. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00115-19 · Cited by 262
Metadata
- Authors
- Maldonado, Y. A., Read, J. S., & COMMITTEE ON INFECTIOUS DISEASES
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2017-02-01
- Volume
- 139
- Issue
- 2
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2580771590
- Cited by
- 270
- References
- 111
- FWCI
- 15.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. https://app.cochat.ai/papers/10.1542/peds.2016-3860
- The paper
- Maldonado, Y. A., Read, J. S., & COMMITTEE ON INFECTIOUS DISEASES. (2017). Diagnosis, Treatment, and Prevention of Congenital Toxoplasmosis in the United States. Pediatrics. https://doi.org/10.1542/peds.2016-3860
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.